Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for BioRestorative Therapies (BRTX) over the last 15 years, with Q3 2025 value amounting to -$951670.0.

  • BioRestorative Therapies' Net Cash Flow fell 2475.96% to -$951670.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$913210.0, marking a year-over-year increase of 725.25%. This contributed to the annual value of -$336487.0 for FY2024, which is 5942.98% up from last year.
  • According to the latest figures from Q3 2025, BioRestorative Therapies' Net Cash Flow is -$951670.0, which was down 2475.96% from $320329.0 recorded in Q2 2025.
  • Over the past 5 years, BioRestorative Therapies' Net Cash Flow peaked at $19.9 million during Q4 2021, and registered a low of -$11.4 million during Q3 2022.
  • Its 5-year average for Net Cash Flow is -$151022.1, with a median of -$629364.0 in 2021.
  • The largest annual percentage gain for BioRestorative Therapies' Net Cash Flow in the last 5 years was 58986.91% (2021), contrasted with its biggest fall of 1819056.48% (2021).
  • Quarter analysis of 5 years shows BioRestorative Therapies' Net Cash Flow stood at $19.9 million in 2021, then tumbled by 124.38% to -$4.9 million in 2022, then skyrocketed by 67.29% to -$1.6 million in 2023, then surged by 40.77% to -$941554.0 in 2024, then decreased by 1.07% to -$951670.0 in 2025.
  • Its Net Cash Flow stands at -$951670.0 for Q3 2025, versus $320329.0 for Q2 2025 and $659685.0 for Q1 2025.